Allarity Therapeutics Inc (ALLR)

Form 8-K - Current report

Allarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple Cancers

- Stenoparib clinical development continues in relapsed small cell lung cancer and, under FDA Fast Track...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Allarity Therapeutics CEO to Present at Precision Medicine Forum Europe 2026 in Stockholm

         TARPON SPRINGS, Fla., May 8, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”...

Form 8-K - Current report

Allarity Therapeutics Advances Stenoparib Toward Pivotal Development with Phase 3 Manufacturing Campaign

         Phase 3 manufacturing campaign on track for completion no later than third quarter 2026, supporting...

Form ARS - Annual Report to Security Holders

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form DEF 14A - Other definitive proxy statements

Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]

Form 8-K - Current report

Allarity Therapeutics Announces that the Stenoparib DRP® Test Has Received a Notice of Allowance from the US Patent and Trademark Office

Patent expected to be formally granted within three months, subject to standard administrative proceduresPatent...

Form 424B3 - Prospectus [Rule 424(b)(3)]